Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cloxacillin Sodium

FDA-approved product (for solution, oral), marketed as Cloxacillin Sodium, Cloxapen, Tegopen.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Cloxacillin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Beta-lactamase resistant penicillins
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01CF02

Repurposing investigation

Cloxacillin Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA20.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli27.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae69.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis43.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • K. pneumoniae: measured active in 1 of 1 lab record
Open Cloxacillin Sodium in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cloxacillin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Determinants of Warfarin Metabolism

    NCT00162474 · start 2003-09

    Registered record
    Registry ID
    NCT00162474
    Conditions
    Healthy
    Interventions
    Warfarin; Phenytoin; Losartan & Hydrochlorothiazide; Flurbiprofen; Siponimod; Dicloxacillin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2003-09
    Completion
    2030-12
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionWarfarin; Phenytoin; Losartan & Hydrochlorothiazide; Flurbiprofen +2 more
    PhaseNot applicable
    Registry statusRecruiting

  • Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia

    NCT00062647 · start 2003-08

    Registered record
    Registry ID
    NCT00062647
    Conditions
    Gram-Positive Bacterial Infections
    Interventions
    Telavancin; Vancomycin, nafcillin, oxacillin, or cloxacillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-08
    Completion
    2006-08
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGram-Positive Bacterial Infections
    InterventionTelavancin; Vancomycin, nafcillin, oxacillin, or cloxacillin
    PhasePhase 2
    Registry statusCompleted

  • Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria

    NCT00037050 · start 2002-04

    Registered record
    Registry ID
    NCT00037050
    Conditions
    Bacterial Infections; Gram-Positive Bacterial Infections; Bacteremia
    Interventions
    Linezolid; Vancomycin; Oxacillin; Dicloxacillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-04
    Completion
    2005-07
    Enrolment
    739

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infections; Gram-Positive Bacterial Infections; Bacteremia
    InterventionLinezolid; Vancomycin; Oxacillin; Dicloxacillin
    PhasePhase 3
    Registry statusCompleted

  • Study of Acupuncture and Care Interventions for the Treatment of Breast Inflammation During Breastfeeding

    NCT00405158 · start 2002-01

    Registered record
    Registry ID
    NCT00405158
    Conditions
    Mastitis
    Interventions
    Acupuncture treatment; Administration of oxytocin nasal spray; Improved breast milk removal; Warmth applied to breasts; Breast massage; Anti-pyretic medication, paracetamol; cefadroxil; penicillin; flucloxacillin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2002-01
    Completion
    2004-03
    Enrolment
    210

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMastitis
    InterventionAcupuncture treatment; Administration of oxytocin nasal spray; Improved breast milk removal; Warmth applied to breasts +5 more
    PhaseNot applicable
    Registry statusCompleted

  • Cefazolin Versus Antistaphylococcal Penicillins for Methicillin Susceptible Staphylococcus Aureus Bacteremia

    NCT07186894 · start 2000-01-01

    Registered record
    Registry ID
    NCT07186894
    Conditions
    Bacteriemia; Methicillin Susceptible Staphylococcus Aureus (MSSA) Infection
    Interventions
    Antistaphylococcal penicillins; Cefazolin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2000-01-01
    Completion
    2026-09-01
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacteriemia; Methicillin Susceptible Staphylococcus Aureus (MSSA) Infection
    InterventionAntistaphylococcal penicillins; Cefazolin
    PhaseNot recorded
    Registry statusActive not recruiting